HOMA2-B可增强TrialNet Pathway to Prevention参与者中1型糖尿病风险评估
本研究基于TrialNet Pathway to Prevention研究中单抗体阳性(n=2652)和多抗体阳性(n=3794)个体,评估基线HOMA2-B与1型糖尿病进展的关联。Cox模型显示最低HOMA2-B三分位者进展风险更高且更快;ROC分析中HOMA2-B联合其他因素在单抗体阳性组2年进展风险AUC-ROC最高(0.723)。提示HOMA2-B可作为单时间点指标用于抗体阳性个体1型糖尿病风险分层。
要点
- 单抗体阳性者基线HOMA2-B高于多抗体阳性者(91.1±44.5 vs 83.9±38.9;p<0.001)。
- 最低HOMA2-B三分位者1型糖尿病进展风险更高且速度更快。
- HOMA2-B联合胰岛素敏感性、年龄和HLA状态可提升风险预测。
核心结论
- HOMA2-B可能作为单时间点测量工具,用于抗体阳性个体1型糖尿病风险分层。
研究设计与样本
- 基于TrialNet Pathway to Prevention研究的队列分析,纳入单抗体阳性(n=2652;平均年龄21.1±14.0岁)和多抗体阳性(n=3794;平均年龄14.5±11.2岁)个体。
- 采用Cox比例风险模型分析HOMA2-B三分位与进展至1型糖尿病时间的关联,并调整年龄、性别、HLA状态和BMI z评分。
- 采用ROC分析检验HOMA2-B与1年、2年、5年和10年内1型糖尿病发生的关联。
主要发现
- 研究入组时,单抗体阳性者HOMA2-B值高于多抗体阳性者(91.1±44.5 vs 83.9±38.9;p<0.001)。
- 单抗体阳性和多抗体阳性个体中,最低HOMA2-B三分位者进展至1型糖尿病的风险更高且速度更快。
- 对于1年内进展至1型糖尿病,全部抗体阳性、单抗体阳性和多抗体阳性个体的AUC-ROC分别为0.685、0.666和0.680。
- 当HOMA2-B与胰岛素敏感性、年龄和HLA状态联合评估时,单抗体阳性组2年进展风险的AUC-ROC最高(0.723 [95% CI 0.652, 0.794])。
临床怎么用
- 在抗体阳性个体中,可考虑使用基线HOMA2-B三分位辅助识别1型糖尿病进展高风险者。
- HOMA2-B联合胰岛素敏感性、年龄和HLA状态可能改善短期进展风险预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Methods to identify individuals at highest risk for type 1 diabetes are essential for the successful implementation of disease-modifying interventions. Simple metabolic measures are needed to help stratify autoantibody-positive (Aab+) individuals who are at risk of developing type 1 diabetes. HOMA2-B is a validated mathematical tool commonly used to estimate beta cell function in type 2 diabetes using fasting glucose and insulin. The utility of HOMA2-B in association with type 1 diabetes progression has not been tested. METHODS: Baseline HOMA2-B values from single-Aab+ (n = 2652; mean age, 21.1 ± 14.0 years) and multiple-Aab+ (n = 3794; mean age, 14.5 ± 11.2 years) individuals enrolled in the TrialNet Pathway to Prevention study were compared. Cox proportional hazard models were used to determine associations between HOMA2-B tertiles and time to progression to type 1 diabetes, with adjustments for age, sex, HLA status and BMI z score. Receiver operating characteristic (ROC) analysis was used to test the association of HOMA2-B with type 1 diabetes development in 1, 2, 5 and 10 years. RESULTS: At study entry, HOMA2-B values were higher in single- compared with multiple-Aab+ Pathway to Prevention participants (91.1 ± 44.5 vs 83.9 ± 38.9; p < 0.001). Single- and multiple-Aab+ individuals in the lowest HOMA2-B tertile had a higher risk and faster rate of progression to type 1 diabetes. For progression to type 1 diabetes within 1 year, area under the ROC curve (AUC-ROC) was 0.685, 0.666 and 0.680 for all Aab+, single-Aab+ and multiple-Aab+ individuals, respectively. When correlation between HOMA2-B and type 1 diabetes risk was assessed in combination with additional factors known to influence type 1 diabetes progression (insulin sensitivity, age and HLA status), AUC-ROC was highest for the single-Aab+ group's risk of progression at 2 years (AUC-ROC 0.723 [95% CI 0.652, 0.794]). CONCLUSIONS/INTERPRETATION: These data suggest that HOMA2-B may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in Aab+ individuals.
引用
- Felton JL, Cuthbertson D, Warnock M, et al. HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. Diabetologia. 2021. PMID: 34642772. doi:10.1007/s00125-021-05573-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。